1 November 2018
Scancell Holdings Plc
("Scancell" or the "Company")
Scancell to present at the Proactive Investors One2One Investor Forum
Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, will today be presenting at the Proactive Investors One2One Investor Forum. The investor forum is being held today at 18.00 GMT at the Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, London.
Dr Cliff Holloway, Chief Executive Officer of Scancell, will be presenting an overview of the Company and will be available to take questions following the event.
For Further Information:
Scancell Holdings Plc |
|
|
Dr John Chiplin, Chairman |
|
+44 (0) 20 3727 1000 |
Dr Cliff Holloway, CEO |
|
|
|
|
|
Panmure Gordon (UK) Limited (Nominated Adviser and Corporate broker) |
|
|
Freddy Crossley/Emma Earl |
|
+44 (0) 20 7886 2500 |
|
|
|
FTI Consulting Mo Noonan/Simon Conway |
|
+44 (0) 20 3727 1000 |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They can be used as monotherapy or in combination with checkpoint inhibitors. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.
· SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.
· SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK for SCIB2.
Moditope® represents a completely new class of potent and selective immunotherapy agents. It stimulates the production of killer CD4+ T cells which overcome the immune suppression induced by tumours. allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.
· Modi-1 is being developed for the treatment of triple negative breast cancer, ovarian cancer and sarcomas.
For further details, please see our website: www.scancell.co.uk
